<https://helda.helsinki.fi>

Elevated cerebrospinal fluid protein in POLG-related epilepsy : Diagnostic and prognostic implications

Hikmat, Omar

2018-08

Hikmat , O , Naess , K , Engvall , M , Klingenberg , C , Rasmussen , M , Tallaksen , C M E ,
Brodtkorb , E , Fiskerstrand , T , Isohanni , P , Uusimaa , J , Darin , N , Rahman , S &
Bindoff , L A 2018 , ' Elevated cerebrospinal fluid protein in POLG-related epilepsy :
Diagnostic and prognostic implications ' , Epilepsia , vol. 59 , no. 8 , pp. 1595-1602 . <https://doi.org/10.1111/epi.14459>

<http://hdl.handle.net/10138/305974>

<https://doi.org/10.1111/epi.14459>

unspecified

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Elevated cerebrospinal fluid protein in *POLG*-related epilepsy: Diagnostic and prognostic implications

Omar Hikmat^{1,2} | Karin Naess^{3,4} | Martin Engvall^{3,5} | Claus Klingenberg^{6,7} |
 Magnhild Rasmussen^{8,9} | Chantal M. E. Tallaksen^{10,11} | Eylert Brodtkorb^{12,13} |
 Torunn Fiskerstrand^{14,15} | Pirjo Isohanni^{16,17} | Johanna Uusimaa^{18,19} | Niklas Darin²⁰ |
 Shamima Rahman^{21,22} | Laurence A. Bindoff^{2,23}

¹Department of Pediatrics, Haukeland University Hospital, Bergen, Norway

²Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway

³Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden

⁴Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden

⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

⁶Department of Pediatric and Adolescent Medicine, University Hospital of North Norway, Tromsø, Norway

⁷Pediatric Research Group, Department of Clinical Medicine, UiT–Arctic University of Norway, Tromsø, Norway

⁸Women and Children's Division, Department of Clinical Neurosciences for Children, Oslo University Hospital, Oslo, Norway

⁹Unit for Congenital and Hereditary Neuromuscular Disorders, Department of Neurology, Oslo University Hospital, Oslo, Norway

¹⁰Department of Neurology, Oslo University Hospital, Oslo, Norway

¹¹Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

¹²Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

¹³Department of Neurology and Clinical Neurophysiology, St. Olav's University Hospital, Trondheim, Norway

¹⁴Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

¹⁵Department of Clinical Science (K2), University of Bergen, Bergen, Norway

¹⁶Department of Pediatric Neurology, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

¹⁷Research Programs Unit, Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

¹⁸PEDEGO Research Unit and Biocenter Oulu, University of Oulu, Oulu, Finland

¹⁹Department of Children and Adolescents, Medical Research Center, Oulu University Hospital, Oulu, Finland

²⁰Department of Pediatrics, Queen Silvia Children's Hospital, University of Gothenburg, Gothenburg, Sweden

²¹Mitochondrial Research Group, University College London Great Ormond Street Institute of Child Health, London, UK

²²Metabolic Unit, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, UK

²³Department of Neurology, Haukeland University Hospital, Bergen, Norway

Correspondence

Laurence Bindoff, Department of
Neurology, University of Bergen,
Haukeland University Hospital, Bergen,
Norway.
Email: laurence.bindoff@nevro.uib.no

Funding information

Western Norway Regional Health
Authority (Helse-Vest), Grant/Award
Number: 911944; Helsinki University
Hospital

Summary

Objective: Epilepsy is common in individuals with mutations in *POLG*, the gene encoding the catalytic subunit of the mitochondrial DNA polymerase gamma. Early recognition and aggressive seizure management are crucial for patient survival. Disruption of the blood-brain barrier (BBB) is implicated in various neurological disorders including epilepsy. The aim of this study was to assess whether *POLG*-related disease is associated with BBB dysfunction and what clinical implications this has for patients.

Methods: Our retrospective study used data from 83 patients with pathogenic *POLG* mutations from 4 countries—Norway, Sweden, Finland, and the United Kingdom. Data were collected using a structured questionnaire. We used the presence of raised cerebrospinal fluid (CSF) protein and a raised CSF/serum ratio of albumin (Q-alb) to evaluate the integrity of the blood-CSF barrier.

Results: Raised CSF protein was found in 70% of patients ($n = 58/83$) and appeared to be associated with the most severe phenotypes. In those in whom it was measured, the Q-alb ratio was markedly elevated ($n = 18$). The majority of those with epilepsy ($n = 50/66$, 76%) had raised CSF protein, and this preceded seizure debut in 75% ($n = 15/20$). The median survival time from symptom onset for those with raised CSF protein was decreased (13 months) compared to those with normal CSF protein (32 months).

Significance: Our results indicate that there is disruption of the BBB in *POLG*-related disease, as evidenced by a raised CSF protein and Q-alb ratio. We also find that raised CSF protein is a common finding in patients with *POLG* disease. Our data suggest that the presence of BBB dysfunction predicts a poorer outcome, and elevated CSF protein may therefore be an additional biomarker both for early diagnosis and to identify those at high risk of developing epilepsy.

KEYWORDS

blood-brain barrier, CSF protein, CSF/serum ratio of albumin, epilepsy, mitochondria, *POLG*

1 | INTRODUCTION

Mitochondria perform a number of important functions, including a major role in energy metabolism. Oxidative phosphorylation (OXPHOS), the enzyme pathway responsible for adenosine triphosphate (ATP) production, contains 13 subunits encoded by mitochondrial DNA (mtDNA), whereas the remaining subunits, together with >1000 other proteins required for mitochondrial structure and function, are encoded in the nuclear DNA.¹ The diagnosis of mitochondrial disorders remains challenging, and currently no effective treatments exist for the majority of these disorders.

POLG is a nuclear gene that encodes the catalytic subunit of DNA polymerase γ , the enzyme responsible for mtDNA replication and repair.² Mutations in *POLG* cause disease that varies in severity from devastating infantile phenotypes such as Alpers syndrome and myocerebrohepatoopathy spectrum (MCHS) to juvenile syndromes comprising epilepsy and ataxia^{3–5} and to late onset myopathies with progressive external ophthalmoplegia (PEO).^{6,7} Epilepsy is particularly common in the early childhood and juvenile groups^{3,4,8–10}; focal seizures, commonly evolving into bilateral convulsive seizures,^{11,12} are the most common seizure types in both adult and pediatric patients, with epileptiform discharges predominantly occurring over the occipital regions.¹³ The majority of the patients develop therapy-resistant epilepsy.^{9,10}

Key Points

- Epilepsy is very common in individuals with *POLG* disease and associated with high morbidity and mortality
- Mutations in *POLG* are associated with progressive disruption of the blood-brain barrier
- Raised CSF protein is commonly seen in patients with *POLG* disease, especially in those with severe phenotypes
- CSF protein can be used as a biomarker to identify those with high risk of developing epilepsy

The blood-brain barrier (BBB) is formed by a continuous layer of cerebral endothelial cells held together by tight junctions (Figure 1), separating the blood components from the brain microenvironment and regulating the entry and exit of ions, nutrients, macromolecules, and energy metabolites. The BBB is a part of the neurovascular unit that includes blood vessels, neurons, astrocytes, pericytes, and microglia, and that is divided into several compartments: the BBB, the blood–cerebrospinal fluid (CSF) barrier, the arachnoid barrier, neuroependyma (the fetal-CSF brain barrier), and adult ependyma (free exchange).¹⁴ Accumulating research suggests that disruption of the BBB contributes to

FIGURE 1 Schematic representation of events that we hypothesize are involved in blood-brain barrier (BBB) dysfunction and epilepsy in individuals with *POLG* disease. *POLG* mutations induce a mitochondrial dysfunction that leads to disruption of the BBB tight junctions and leakage of proteins such as albumin. Uptake of proteins by astrocytes and neurons initiates a cascade of events (downregulation of extracellular potassium buffering capacity, *N*-methyl-D-aspartate receptor-mediated neuronal hyperexcitability, and the release of pro-inflammatory cytokines) that contribute to seizure development

the pathophysiology of various acute and chronic neurological disorders (Table 1).^{15–19}

OXPHOS deficiency in central nervous system microvasculature, including vascular smooth muscle cell layer and endothelial cells, has been reported previously.^{20–22} Evidence of BBB dysfunction, with plasma protein extravasation, has been suggested by the findings of raised CSF protein,³ but has only been demonstrated on postmortem examination in a single patient with *POLG* disease.²²

Given that *POLG*-related disease causes both a progressive encephalopathy and aggressive epilepsy, the aims of this study were to investigate whether BBB dysfunction occurs in *POLG* disease and, if so, what the consequences are for affected patients. Our rationale was that greater understanding of the mechanisms driving *POLG*-related disease has the potential to provide us with both new biomarkers to facilitate earlier diagnosis and novel therapeutic targets.

2 | MATERIALS AND METHODS

2.1 | Study design and population

We conducted a multinational, retrospective study of patients from 9 centers in 4 European countries: Norway

(Haukeland University Hospital, Oslo University Hospital, St. Olav's Hospital, and University Hospital of Northern Norway), the United Kingdom (Great Ormond Street Hospital), Sweden (Center for Inherited Metabolic Diseases, Karolinska University Hospital and Queen Silvia Children's Hospital, University of Gothenburg), and Finland (Children's Hospital and University Hospital, Helsinki and Department of Children and Adolescents, Oulu University Hospital). Patients from these centers with pathogenic *POLG* mutations were included.

Patients were classified phenotypically into 6 groups, including (1) Alpers syndrome; (2) MCHS; (3) myoclonic epilepsy, myopathy, sensory ataxia (MEMSA); (4) ataxia neuropathy spectrum (ANS); and (5) autosomal dominant and autosomal recessive progressive external ophthalmoplegia. Classification was based on previously described criteria.^{6,23} Patients who did not fulfil the clinical criteria for the above phenotypes were reported as (6) "other." The study cohort as a whole was also classified into 2 groups according to the presence or absence of epilepsy. Therapy-resistant epilepsy was defined using the International League against Epilepsy definition.²⁴

Ethical approval was obtained from the Regional Committee for Medical and Health Research Ethics, Western Norway (REK 2014/1783-4). Each participating center also

TABLE 1 Neurological conditions associated with raised CSF protein and Q-alb ratio

Neurological disorder, reference	Q-alb ratio $\times 10^{-3}$ median (range)
Multiple sclerosis ¹⁵	
Pattern I	4.8 (3.0-10.8)
Pattern II	7.3 (2.1-33.9)
Pattern III	9.0 (3.3-20.7)
Alzheimer's ¹⁶	
Early onset	5.4 (4.1-7.7)
Late onset	6.3 (4.9-8.2)
Amyotrophic lateral sclerosis ¹⁷	
Parkinson's ¹⁶	7.4 (5.6-10.5)
Viral meningitis ¹⁸	9.1 (7.2-14.7)
Ischemic stroke ¹⁹	
Territorial	11.1 (7.8-14.4)
Lacunar	9.7 (7.9-18.5)
Guillain-Barre syndrome ¹⁷	16 (9-55)
Lyme disease ¹⁸	17.2 (9.7-28.4)
Bacterial meningitis ¹⁷	18 (6-69)
<i>POLG</i> -related disorders ^a	21.5 (14.2-56.8)

CSF, cerebrospinal fluid; Q-alb, CSF to serum albumin.

^aStudy data.

obtained approval from its local ethical committee. The study was registered as an audit at Great Ormond Street Hospital, London, UK.

2.2 | Clinical and laboratory data

Patient's data were collected using an electronic case report form. Clinical data included age at onset of symptoms requiring medical evaluation, detailed medical history, phenotype, and survival status or date of last follow-up.

Laboratory data included hepatic aminotransferase, blood and CSF lactate, muscle respiratory chain enzyme activities, muscle histology findings, and genetic findings. CSF protein and/or albumin values at disease onset and during the disease course were recorded. Because the reference range for CSF protein may be age dependent, we have looked at the values according to age,^{19,25,26} and the cutoff values used in this study are reported in Table S1. CSF samples artificially contaminated with blood as a complication of lumbar puncture were not included, and none of the individuals included in this study had clinical or laboratory evidence of meningitis or encephalitis.

Because albumin is produced exclusively in the liver, all albumin detected in CSF originates from blood. The level of CSF albumin provides, therefore, a parameter with

which to evaluate the permeability of the blood-CSF barrier. The ratio of CSF to serum albumin (Q-alb) corrects for the individual's albumin level and provides a reflection of the diffusion gradient of albumin.^{27,28} This ratio was calculated as CSF albumin (mg/L)/serum albumin (g/L). The reference range for Q-alb is age dependent; the cutoffs used in this study are reported in Table S2.^{19,27-29}

2.3 | Statistical analysis

Data were analyzed using SPSS version 23.0 (Armonk, NY, USA). Results were considered statistically significance with a 2-sided *P* value of <.05. Survival was defined by the endpoint—time to death, which was defined as the interval in months from the onset of symptoms to the date of death. A comparison of survival time between clinical categories was performed using log-rank test (Kaplan-Meier).

3 | RESULTS

3.1 | Demography

Eighty-three patients, (39 male, 44 female) were identified. Fifty patients were diagnosed in Norway, 19 in Sweden, 9 in the United Kingdom, and 5 in Finland. Median age of onset for the group as a whole was 9 months (range = 3 weeks to 67 years). The majority of patients were Northern European (*n* = 78), with 3 patients from Iraq and 2 from Cyprus.

3.2 | Phenotype spectrum

Thirty-seven patients fulfilled diagnostic criteria for Alpers, 30 for MEMSA, 8 for ANS, 3 for PEO, 2 for MCHS. Three patients did not fulfil the diagnostic criteria for the

TABLE 2 Percentages of normal and abnormal CSF total protein according to *POLG*-related phenotypes

Phenotype	Abnormal CSF protein, n (%)	Normal CSF protein, n (%)	Total
Alpers	30 (81%)	7 (19%)	37
MCHS	2 (100%)	0 (0%)	2
MEMSA	20 (67%)	10 (33%)	30
ANS	4 (50%)	4 (50%)	8
PEO	1 (33%)	2 (67%)	3
Other	1 (33%)	2 (67%)	3
Total	58 (70%)	25 (30%)	83

ANS, ataxia neuropathy spectrum; CSF, cerebrospinal fluid; MCHS, myocerebrohepatopathy spectrum; MEMSA, myoclonic epilepsy, myopathy, sensory ataxia; PEO, progressive external ophthalmoplegia.

above phenotypes and were classified as “other” (1 with a Leigh-like phenotype, 1 with a mitochondrial neurogas-trointestinal encephalopathy-like phenotype, and 1 with epilepsy and transient mild elevation in liver function tests; Table 2).

3.3 | Laboratory findings

Laboratory investigations (Table 3) revealed that 59% ($n = 42/71$) had elevated serum lactate, 61% ($n = 27/54$) had elevated CSF lactate, and 65% ($n = 54/82$) had elevated hepatic aminotransferase levels. Muscle biopsy and respiratory chain analysis showed that 53% ($n = 35/66$) had abnormal histological findings, defined by the presence of ragged red fibers and/or COX-negative fibers, and 47% ($n = 14/30$) had abnormal respiratory chain activities; the majority (71%, $n = 10/14$) were in individuals with raised CSF protein/albumin.

Raised CSF protein and/or albumin was found in 70% ($n = 58/83$) at some point during the disease course and in 65% ($n = 48/73$) it was present at disease onset. Seventy-one percent ($n = 30/42$) had abnormal CSF protein and/or albumin measured later in the disease course. The level of CSF protein increased with disease duration; a median value of 0.83 g/L (range = 0.53–6.00) at disease onset rose to 1.04 g/L (range 0.74–4.24) later. In 12 patients, longitudinal data showed that CSF protein increased with time; median CSF protein at onset was 0.94 g/L (range = 0.57–2.5), rising to 1.18 (range = 0.8–4.2) later in the disease. The frequency of abnormal elevated CSF protein according to each specific phenotype is provided in Table 2.

3.4 | CSF protein and epilepsy

Eighty percent ($n = 66/83$) of the study cohort had epilepsy (focal onset, focal to bilateral tonic–clonic, generalized onset, myoclonic, epilepsy partialis continua, and status epilepticus), and in 76% ($n = 50/66$) of these, CSF protein

was raised regardless of seizure type. Median total CSF protein for those with status epilepticus was 1.04 g/L (range = 0.8–2.6). Further analysis showed that 75% ($n = 15/20$) of those who developed epilepsy later in the disease course had raised CSF protein at disease onset and that the majority of those with abnormal raised CSF protein (85%, $n = 45/53$) had therapy-resistant epilepsy.

3.5 | Evidence of blood-CSF barrier dysfunction

Serum albumin and CSF albumin values taken simultaneously were available for 18 patients, allowing calculation of the Q-alb ratio. All cases showed a markedly raised Q-alb ratio, with median value = 21.5×10^{-3} (range = 14.2×10^{-3} – 56.8×10^{-3}).

3.6 | Genetics findings

Pathogenic *POLG* variants for each case were identified either by targeted mutation analysis for specific common mutations (c.1399G>C, p.Ala467Thr and c.2243G>C, p.Trp748Ser) or by sequence analysis of all coding regions of *POLG*. Further analysis showed that there was no clear association between specific genotype and raised CSF protein.

3.7 | Survival analysis

Median survival time from symptom onset for those with normal CSF protein was 32 months, compared to 13 months for those with abnormal CSF protein. Although not statistically significant ($P = .08$), Kaplan-Meier curve analysis showed a clear trend of worse survival for those with abnormal CSF protein (Figure S1).

4 | DISCUSSION

Our study evaluated the question of whether *POLG* disease is associated with BBB dysfunction, as had been suggested by a previous histological study.²² Using clinical and laboratory data from 83 individuals, we analyzed the frequency of abnormally raised CSF protein and evaluated the integrity of the brain barrier by measuring the Q-alb ratio.^{27,28} We found that more than two-thirds of patients (70%) had raised CSF protein and/or albumin. The Q-alb ratio was markedly raised in the 18 patients in whom this was measured (median value = 21.5×10^{-3}), indicating a major dysfunction in the BBB. When compared with other disorders in which BBB dysfunction occurs, the Q-alb ratio was among the highest recorded, suggesting that *POLG*-related disease profoundly affects BBB integrity (Table 1).

TABLE 3 Major laboratory findings in patients with *POLG*-related diseases

Laboratory test	Percentage, %
Elevated blood lactate	59% ($n = 42/71$)
Elevated hepatic aminotransferase	65% ($n = 54/82$)
Elevated CSF lactate	61% ($n = 27/54$)
Elevated CSF protein	70% ($n = 58/83$)
Muscle pathology (RRF, COX)	53% ($n = 35/66$)
Abnormal RC activities	47% ($n = 14/30$)

COX, cytochrome oxidase; CSF, cerebrospinal fluid; RC, respiratory chain; RRF, ragged red fibers.

Furthermore, our results showed that there was a progressive deterioration in the BBB integrity, as both the proportion of those with abnormal raised CSF protein and the actual CSF protein value increased with time.

When we compared the proportion of individuals with abnormal CSF protein and/or albumin to those having abnormalities of more commonly used biomarkers, we found that the proportion of those with elevated protein/albumin was higher (Table 3). This suggests that elevated CSF protein has a higher diagnostic sensitivity for *POLG*-related disease than lactate or the other commonly used biomarkers.

The presence of raised CSF protein was particularly common in patients with early onset, severe disease phenotypes (eg, Alpers, MCHS, and MEMSA phenotypes; Table 2). The median survival time from symptom onset for those with raised CSF protein was markedly decreased (13 months) compared to those with normal CSF protein (32 months). Elevated CSF protein showed a clear association with disease severity and with the presence of epilepsy, another major prognostic factor. Our analysis showed that 76% of *POLG* patients with epilepsy had raised CSF protein irrespective of seizure type; that is, because patients with focal seizures also develop status epilepticus, it is not possible from our data to assess whether one seizure type was associated with higher CSF protein. Interestingly, the presence of elevated CSF protein, and thus the possibility of BBB dysfunction, preceded the onset of the seizures ($n = 15/20$). Our study demonstrates, therefore, not only the diagnostic relevance of measuring CSF protein, but also its clinical importance as a biomarker in the early identification of patients with a high risk of developing epilepsy.

The relationship between BBB disruption and epilepsy has been described both in animal models and in patients.^{30–34} Large molecular proteins such as albumin that cross an impaired BBB can be taken up by neurons or astrocytes; uptake into neurons occurs by unknown mechanisms, but entry into astrocytes is via the TGF- β receptor.³⁵ Uptake is followed by downregulation of extracellular potassium buffering capacity,³⁶ which facilitates *N*-methyl-D-aspartate receptor-mediated neuronal hyperexcitability^{34,37} and the release of pro-inflammatory cytokines.^{35,38,39} All of these mechanisms may either lead to seizures or lower the threshold for seizure initiation.^{30,34,40} In addition, manipulating mitochondrial function in vitro by inhibition of complex I with rotenone, impairing ATP production using carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone, or inhibiting complex V with oligomycin can also produce rapid changes in BBB permeability.⁴¹ Furthermore, the same study demonstrated that inhibition of mitochondrial respiratory chain activity in mice, by epidural administration of rotenone, impaired

BBB integrity and was associated with marked increase in BBB permeability.⁴¹

Based on our findings and work by others,^{30,34,35,41} we suggest a potential mechanism: *POLG* mutations induce a mitochondrial dysfunction that leads to disruption of the BBB tight junctions and leakage of proteins such as albumin. Uptake of proteins by astrocytes and neurons initiates a cascade of events that contribute to seizure development (Figure 1) and subsequent worsening of the BBB dysfunction. Furthermore, we believe that the raised CSF protein is itself evidence of impaired BBB integrity and a valuable biomarker that can identify those at high risk of developing epilepsy and, by extrapolation, those with a poor prognosis. Based on our findings, we recommend that CSF protein and Q-alb status are measured in all patients presenting with undiagnosed encephalopathy, and that those with *POLG*-related disease with raised CSF protein are closely monitored with frequent electroencephalographic recordings to facilitate early recognition and immediate seizure treatment.

5 | ETHICAL PUBLICATION STATEMENT

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The ethical approved for the study was obtained from the Regional Committee for Medical and Health Research Ethics, Western Norway (REK 2014/1783-4). Each participating country had obtained approval from the local ethical committee. The study was registered as an audit at Great Ormond Street Hospital, London, UK (registration number 1675).

ACKNOWLEDGMENTS

This work was supported by grants from the Western Norway Regional Health Authority (Helse-Vest, grant 911944). P.I. is supported by a grant from the special governmental subsidy for health sciences research of Helsinki University Hospital. We thank adjunct professor Geir Egil Eide, Department of Global Public Health and Primary Care, Bergen University, Bergen, Norway for his help with the statistical analysis.

DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Omar Hikmat <http://orcid.org/0000-0002-9497-736X>

REFERENCES

1. Smeitink J, van den Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. *Nat Rev Genet*. 2001;2:342–52.
2. Longley MJ, Graziewicz MA, Bienstock RJ, et al. Consequences of mutations in human DNA polymerase gamma. *Gene*. 2005;354:125–31.
3. Winterthun S, Ferrari G, He L, et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. *Neurology*. 2005;64:1204–8.
4. Tzoulis C, Engelsens BA, Telstad W, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. *Brain*. 2006;129:1685–92.
5. Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. *Am J Hum Genet*. 2005;77:430–41.
6. Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. *GeneReviews*. Seattle, WA: University of Washington; 2010.
7. Chan SS, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. *Biochim Biophys Acta*. 2009;1787:312–9.
8. Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. *Brain*. 2006;129:1674–84.
9. Hikmat O, Tzoulis C, Chong WK, et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. *Genet Med*. 2017;19:1217–25.
10. Hikmat O, Eichele T, Tzoulis C, et al. Understanding the epilepsy in POLG related disease. *Int J Mol Sci*. 2017;18:pii: E1845.
11. Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. *Epilepsia*. 2009;50:1596–607.
12. Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. *Epilepsia*. 2008;49:1038–45.
13. Engelsens BA, Tzoulis C, Karlsen B, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. *Brain*. 2008;131:818–28.
14. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. *Nat Rev Neurosci*. 2011;12:169–82.
15. Jarius S, König FB, Metz I, et al. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. *J Neuroinflammation*. 2017;14:171.
16. Skillback T, Delsing L, Synnergren J, et al. CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. *Neurobiol Aging*. 2017;59:1–9.
17. Yushchenko M, Weber F, Mader M, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. *J Neuroimmunol*. 2000;110:244–51.
18. Djukic M, Schmidt-Samoa C, Lange P, et al. Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. *J Neurol*. 2012;259:630–6.
19. Brettschneider J, Claus A, Kassubek J, et al. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. *J Neurol*. 2005;252:1067–73.
20. Tanji K, Kunimatsu T, Vu TH, et al. Neuropathological features of mitochondrial disorders. *Semin Cell Dev Biol*. 2001;12:429–39.
21. Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. *Neuropathol Appl Neurobiol*. 2006;32:359–73.
22. Lax NZ, Pienaar IS, Reeve AK, et al. Microangiopathy in the cerebellum of patients with mitochondrial DNA disease. *Brain*. 2012;135:1736–50.
23. Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. *Dev Disabil Res Rev*. 2010;16:163–74.
24. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2010;51:1069–77.
25. Hegen H, Auer M, Zeileis A, et al. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. *Clin Chem Lab Med*. 2016;54:285–92.
26. Deisenhammer F, Sellebjerg F, Teunissen CE, et al. *Cerebrospinal fluid in clinical neurology*. Cham, Switzerland: Springer International Publishing Switzerland; 2015.
27. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. *Scand J Clin Lab Invest*. 1977;37:397–401.
28. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *J Neurol Sci*. 2001;184:101–22.
29. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. *Eur Neurol*. 1993;33:129–33.
30. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. *Nat Med*. 2013;19:1584–96.
31. Fieschi C, Lenzi GL, Zanette E, et al. Effects on EEG of the osmotic opening of the blood-brain barrier in rats. *Life Sci*. 1980;27:239–43.
32. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. *Epilepsia*. 2007;48:732–42.
33. Neuwelt EA, Specht HD, Howieson J, et al. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning. *AJR Am J Roentgenol*. 1983;141:829–35.
34. van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. *Semin Cell Dev Biol*. 2015;38:26–34.
35. Ralay Ranaivo H, Wainwright MS. Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. *Brain Res*. 2010;1313:222–31.
36. Kofuji P, Newman EA. Potassium buffering in the central nervous system. *Neuroscience*. 2004;129:1045–56.

37. Coulter DA, Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. *Glia*. 2012;60:1215–26.
38. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. *J Neurosci*. 2009;29:8927–35.
39. Ralay Ranaivo H, Patel F, Wainwright MS. Albumin activates the canonical TGF receptor-smad signaling pathway but this is not required for activation of astrocytes. *Exp Neurol*. 2010;226:310–9.
40. Han H, Mann A, Ekstein D, et al. Breaking bad: the structure and function of the blood-brain barrier in epilepsy. *AAPS J*. 2017;19:973–88.
41. Doll DN, Hu H, Sun J, et al. Mitochondrial crisis in cerebrovascular endothelial cells opens the blood-brain barrier. *Stroke*. 2015;46:1681–9.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Hikmat O, Naess K, Engvall M, et al. Elevated cerebrospinal fluid protein in *POLG*-related epilepsy: Diagnostic and prognostic implications. *Epilepsia*. 2018;59:1595–1602.
<https://doi.org/10.1111/epi.14459>